Skip to main content
Erschienen in: Current Heart Failure Reports 2/2014

01.06.2014 | Management of Heart Failure (TE Meyer, Section Editor)

Polypharmacy in Heart Failure Patients

verfasst von: Vittoria Mastromarino, Matteo Casenghi, Marco Testa, Erica Gabriele, Roberta Coluccia, Speranza Rubattu, Massimo Volpe

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines. With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF treatment, as it often leads to inappropriate drug prescription, poor adherence to pharmacological therapies, drug-drug interactions, and adverse effects. The growing complexity of HF patients, whose mean age increases progressively and who present multiple comorbidities, suggests the need for newer models of primary care to improve the management of HF patients. Self-care, telemonitoring, and natriuretic peptide-guided therapy represent promising new HF care models to face the complexity of the disease and its therapeutic regimen.
Literatur
1.
Zurück zum Zitat Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.PubMedCrossRef Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.PubMedCrossRef
2.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388–442.PubMedCrossRef Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388–442.PubMedCrossRef
3.
Zurück zum Zitat Braunwald E. Heart Failure. JACC HF. 2013;1(1):1–20. Braunwald E. Heart Failure. JACC HF. 2013;1(1):1–20.
4.
Zurück zum Zitat Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226–33.PubMedCrossRef Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42(7):1226–33.PubMedCrossRef
5.
Zurück zum Zitat Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78.PubMedCentralPubMedCrossRef Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol. 1997;53(1):7–11.PubMedCrossRef Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol. 1997;53(1):7–11.PubMedCrossRef
7.
Zurück zum Zitat Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86–8.PubMedCrossRef Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86–8.PubMedCrossRef
8.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef
10.
Zurück zum Zitat Volpe M, Pignatelli G, Paneni F. Polytherapy in cardiovascular prevention: open issues. G Ital Cardiol. 2012;13(7–8):503–10. Volpe M, Pignatelli G, Paneni F. Polytherapy in cardiovascular prevention: open issues. G Ital Cardiol. 2012;13(7–8):503–10.
11.
Zurück zum Zitat Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM. 1997;336(8):525–33.CrossRef Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM. 1997;336(8):525–33.CrossRef
12.
Zurück zum Zitat Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.PubMedCrossRef Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.PubMedCrossRef
13.
Zurück zum Zitat Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. American heart journal. 2002;143(3):412–7.PubMedCrossRef Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. American heart journal. 2002;143(3):412–7.PubMedCrossRef
14.••
Zurück zum Zitat Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–43. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCentralPubMedCrossRef Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–43. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JACC. 2012;59(11):998–1005.PubMedCrossRef Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. JACC. 2012;59(11):998–1005.PubMedCrossRef
16.
Zurück zum Zitat Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Inter Med. 2002;162(15):1689–94.CrossRef Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Inter Med. 2002;162(15):1689–94.CrossRef
17.
Zurück zum Zitat Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail. 2002;4(1):91–8.PubMedCrossRef Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail. 2002;4(1):91–8.PubMedCrossRef
18.
Zurück zum Zitat Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6(2):235–43.PubMedCrossRef Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6(2):235–43.PubMedCrossRef
19.
Zurück zum Zitat Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005;165(18):2069–76.PubMedCrossRef Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med. 2005;165(18):2069–76.PubMedCrossRef
20.
Zurück zum Zitat Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clinic Proc. 2011;86(4):273–81.CrossRef Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clinic Proc. 2011;86(4):273–81.CrossRef
21.
Zurück zum Zitat Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17(3):217–23.PubMedCrossRef Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17(3):217–23.PubMedCrossRef
22.
Zurück zum Zitat Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24(1):9–17.PubMedCrossRef Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24(1):9–17.PubMedCrossRef
23.
Zurück zum Zitat Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607):349–360. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607):349–360.
24.
Zurück zum Zitat Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875):821–828. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875):821–828.
25.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. NEJM. 1992;327(10):669–77.PubMedCrossRef Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. NEJM. 1992;327(10):669–77.PubMedCrossRef
26.
Zurück zum Zitat Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. JACC. 1998;31(2):419–25.PubMedCrossRef Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. JACC. 1998;31(2):419–25.PubMedCrossRef
27.
Zurück zum Zitat Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312–22.PubMedCrossRef Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312–22.PubMedCrossRef
28.
Zurück zum Zitat Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24.PubMedCrossRef Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24.PubMedCrossRef
29.
Zurück zum Zitat Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31(4):199–205.PubMedCrossRef Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31(4):199–205.PubMedCrossRef
30.
Zurück zum Zitat Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.PubMed Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs. 2005;31(9):4–11.PubMed
31.
Zurück zum Zitat Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev. 2012;17(4–5):589–95.PubMedCrossRef Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev. 2012;17(4–5):589–95.PubMedCrossRef
32.
Zurück zum Zitat Ruwald MH, Hansen ML, Lamberts M, et al. Comparison of incidence, predictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients <85 versus >/=85 years of age. American J Cardiol. 2013;112(10):1610–5.CrossRef Ruwald MH, Hansen ML, Lamberts M, et al. Comparison of incidence, predictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients <85 versus >/=85 years of age. American J Cardiol. 2013;112(10):1610–5.CrossRef
34.
Zurück zum Zitat de Miguel DJ, Chancafe Morgan J, Jimenez GR. The association between COPD and heart failure risk: a review. Intern J Chron Obstruct Pulmon Dis. 2013;8:305–12. de Miguel DJ, Chancafe Morgan J, Jimenez GR. The association between COPD and heart failure risk: a review. Intern J Chron Obstruct Pulmon Dis. 2013;8:305–12.
35.
Zurück zum Zitat Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63(6):525–34.PubMedCrossRef Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63(6):525–34.PubMedCrossRef
36.
Zurück zum Zitat Triggiani V, Iacoviello M, Monzani F, et al. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr Metab Immune Disord Drug Targets. 2012;12(1):86–94.PubMedCrossRef Triggiani V, Iacoviello M, Monzani F, et al. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr Metab Immune Disord Drug Targets. 2012;12(1):86–94.PubMedCrossRef
38.
Zurück zum Zitat Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.PubMedCrossRef Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516–23.PubMedCrossRef
39.
Zurück zum Zitat Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, Group OS. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–3.PubMedCentralPubMedCrossRef Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, Group OS. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–3.PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294(10):1240–7.PubMedCrossRef Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294(10):1240–7.PubMedCrossRef
41.
Zurück zum Zitat Komajda M, Hanon O, Hochadel M, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J. 2007;28(11):1310–8.PubMedCrossRef Komajda M, Hanon O, Hochadel M, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J. 2007;28(11):1310–8.PubMedCrossRef
42.
Zurück zum Zitat Sackett DL, Haynes RB. Compliance with therapeutic regimens. The Johns Hopkins University Press; 1976. Sackett DL, Haynes RB. Compliance with therapeutic regimens. The Johns Hopkins University Press; 1976.
43.
Zurück zum Zitat Evangelista LS, Berg J, Dracup K. Relationship between psychosocial variables and compliance in patients with heart failure. Heart Lung. 2001;30(4):294–301.PubMedCrossRef Evangelista LS, Berg J, Dracup K. Relationship between psychosocial variables and compliance in patients with heart failure. Heart Lung. 2001;30(4):294–301.PubMedCrossRef
44.
Zurück zum Zitat Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef
45.•
Zurück zum Zitat Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMed Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMed
46.
Zurück zum Zitat Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am. 2008;43(1):133–53. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am. 2008;43(1):133–53. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef
47.
Zurück zum Zitat Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. JACC. 2004;43(11):2036–43.PubMedCrossRef Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. JACC. 2004;43(11):2036–43.PubMedCrossRef
48.
Zurück zum Zitat Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef
49.
Zurück zum Zitat Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722–32.PubMedCrossRef Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722–32.PubMedCrossRef
50.
51.
Zurück zum Zitat Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–52.PubMedCrossRef Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–52.PubMedCrossRef
52.
Zurück zum Zitat Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80(5):437–41.PubMedCentralPubMed Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80(5):437–41.PubMedCentralPubMed
53.
Zurück zum Zitat Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336(8714):542–5.PubMedCrossRef Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336(8714):542–5.PubMedCrossRef
54.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.PubMedCrossRef Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.PubMedCrossRef
55.
Zurück zum Zitat Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120(12):1141–63.PubMedCrossRef Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120(12):1141–63.PubMedCrossRef
56.
Zurück zum Zitat Moser DK, Dickson V, Jaarsma T, Lee C, Stromberg A, Riegel B. Role of self-care in the patient with heart failure. Curr Cardiol Rep. 2012;14(3):265–75.PubMedCrossRef Moser DK, Dickson V, Jaarsma T, Lee C, Stromberg A, Riegel B. Role of self-care in the patient with heart failure. Curr Cardiol Rep. 2012;14(3):265–75.PubMedCrossRef
57.••
Zurück zum Zitat Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(2):115–26. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(2):115–26. This is an excellent analysis of the data from NHANES that show a progressive change in the characteristics of the HF population over the last two decades. PubMedCrossRef
58.
Zurück zum Zitat Goldberg LR, Piette JD, Walsh MN, et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J. 2003;146(4):705–12.PubMedCrossRef Goldberg LR, Piette JD, Walsh MN, et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J. 2003;146(4):705–12.PubMedCrossRef
59.
Zurück zum Zitat Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;8, CD007228.PubMed Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;8, CD007228.PubMed
60.
Zurück zum Zitat Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH, Investigators T-H. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. JACC. 2005;45(10):1654–64.PubMedCrossRef Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH, Investigators T-H. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. JACC. 2005;45(10):1654–64.PubMedCrossRef
62.
Zurück zum Zitat Koehler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011;123(17):1873–80.PubMedCrossRef Koehler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011;123(17):1873–80.PubMedCrossRef
63.
Zurück zum Zitat Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–30.PubMedCrossRef Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–30.PubMedCrossRef
64.
Zurück zum Zitat Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Inter Med. 2010;170(6):507–14.CrossRef Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Inter Med. 2010;170(6):507–14.CrossRef
65.
Zurück zum Zitat Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail. 2011;17(8):613–21.PubMedCrossRef Shah MR, Califf RM, Nohria A, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail. 2011;17(8):613–21.PubMedCrossRef
66.
Zurück zum Zitat Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090–100.PubMedCrossRef Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090–100.PubMedCrossRef
67.
Zurück zum Zitat Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003;139(2):137–47.PubMedCrossRef Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003;139(2):137–47.PubMedCrossRef
Metadaten
Titel
Polypharmacy in Heart Failure Patients
verfasst von
Vittoria Mastromarino
Matteo Casenghi
Marco Testa
Erica Gabriele
Roberta Coluccia
Speranza Rubattu
Massimo Volpe
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2014
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-014-0186-8

Weitere Artikel der Ausgabe 2/2014

Current Heart Failure Reports 2/2014 Zur Ausgabe

Management of Heart Failure (TE Meyer, Section Editor)

Interventions for Heart Failure Readmissions: Successes and Failures

Management of Heart Failure (TE Meyer, Section Editor)

Determinants of Survival Following Hospitalization for Acute Heart Failure

Management of Heart Failure (TE Meyer, Section Editor)

Decision-Making Under Uncertainty in Advanced Heart Failure

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.